CN107375757A - A kind of asparagus tablet and preparation method thereof - Google Patents
A kind of asparagus tablet and preparation method thereof Download PDFInfo
- Publication number
- CN107375757A CN107375757A CN201710763490.4A CN201710763490A CN107375757A CN 107375757 A CN107375757 A CN 107375757A CN 201710763490 A CN201710763490 A CN 201710763490A CN 107375757 A CN107375757 A CN 107375757A
- Authority
- CN
- China
- Prior art keywords
- asparagus
- parts
- tablet
- powder
- ultramicro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000005340 Asparagus officinalis Nutrition 0.000 title claims abstract description 82
- 238000002360 preparation method Methods 0.000 title claims description 15
- 244000003416 Asparagus officinalis Species 0.000 title 1
- 241000234427 Asparagus Species 0.000 claims abstract description 81
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 21
- 229930182490 saponin Natural products 0.000 claims abstract description 21
- 150000007949 saponins Chemical class 0.000 claims abstract description 21
- 238000000605 extraction Methods 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 11
- 238000010828 elution Methods 0.000 claims abstract description 11
- 238000005057 refrigeration Methods 0.000 claims abstract description 11
- 238000000227 grinding Methods 0.000 claims abstract description 8
- 238000002604 ultrasonography Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- 239000000843 powder Substances 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 12
- 229920001353 Dextrin Polymers 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 9
- 235000019425 dextrin Nutrition 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- -1 hydroxy-propyl Chemical group 0.000 claims description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 235000015110 jellies Nutrition 0.000 claims description 3
- 239000008274 jelly Substances 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 235000020985 whole grains Nutrition 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 239000012530 fluid Substances 0.000 abstract description 3
- 241000674144 Asparagus albus Species 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 230000000242 pagocytic effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013642 negative control Chemical group 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 241001116389 Aloe Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000931143 Gleditsia sinensis Species 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical group CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of asparagus tablet, it is using fresh white asparagus as raw material, prepared using modes such as vacuum refrigeration, ultramicro grinding, ultrasound-enhanced extraction, extraction, elutions, the asparagus saponin(e high purity 96.2% ~ 97.1% extracted, improve the bioavilability of asparagus, processing cost is reduced, body's immunity, while nourishing generate fluid, killing tumor cell, the medicine for mitigating chemicotherapy side effect can be effectively improved by being prepared for one kind.
Description
Technical field
The present invention relates to drug field, and in particular to a kind of asparagus tablet and preparation method thereof.
Background technology
Asparagus is a kind of fine quality, nutritious health vegetables, contains the indispensable amino acid of human body, mineral
Matter and other various nutrient elements are also high containing the various active composition such as gleditsia sinensis glycoside compound and flavonoids, its nutritive value
In general vegetable and fruit, it is referred to as in the international market " kings of vegetables ".Contain abundant protein, dimension life in asparagus spear
Trace element of element, mineral matter and needed by human body etc., contains distinctive asparagine, and material, to painstaking effort in addition in asparagus
Pipe disease, oedema, cystitis, leukaemia are effective in cure, also there is the effect of anticancer, therefore long-term consumption asparagus has Energy benefit taste, to people
The many diseases of body have good therapeutic effect.
Asparagus food and medicine consangunity, high praise is enjoyed since ancient times.《Legendary god of farming's book on Chinese herbal medicine》Asparagus is classified as " on top grade ", claims " long term usage
Can not only make light of one's life by commiting suicide, also QI invigorating macrobiosis " the effect of.Ming Dynasty's Li Shizhen (1518-1593 A.D.)《Compendium of Materia Medica》Record：" goitre knot hot gas, profit are small for asparagus
Just ", have the effect of moistening lung, antibechic, eliminating the phlegm, desinsection, claim it " all endogenous toxic materials can be solved ".《China's doctor's allusion quotation》Asparagus is even more described in detail and includes reed
Fourth, vitamin C, it can reduce blood pressure, soften blood vessel, reduce cholesterol absorption, can be as hypertension, the dietotherapy side of Coronary Heart Disease Patients
Agent.Asparagus is pharmacologically built up health, improves immunity, be antifatigue, burn fat, protecting liver and detoxication, reducing blood lipid, resist oxygen lack,
Anti-oxidant liver protection, anti-aging, it is antitumor, enhancing memory the effect of.Clinical practice in cancer preventing and treating, treatment high fat of blood, control
Psoriasis, to control breast cancer, the proliferation of mammary gland, hypertension, heart disease, tachycardia, fatigue, oedema, cystitis, lithiasis, urination tired
The diseases such as hardly possible, hepatic sclerosis, can be as the auxiliary treatment food of all kinds of cancer patients.
At present, extraction, the research of purifying of the China to asparagus saponin(e discloses also in starting stage, CN102511802A
A kind of asparagus tablet, it is the vegetable oil of addition 10 ~ 90%, appropriate edible color using 10 ~ 50% instant asparagus powders as raw material
Element, mixed liquid or suspension are closed in tablet shell, although in the asparagus tablet containing asparagus saponin(e reach 80mg with
On, but its preparation technology is complicated, and vegetable oil and food coloring are convenient source, do not have the work strengthened to the health-care efficacy of asparagus
With nutrient composition content has loss, have impact on its health-care efficacy.CN100365011C discloses a kind of production of asparagus saponin
Method, in this method, due to when preparing asparagus saponin(e, precipitating reagent ether and petroleum ether, and ether and petroleum ether are a kind of
Volatile, incendive material, condition control is improper during industrialization, easily triggers accident, causes to be difficult to the loss made up, uncomfortable
Close industrialized production.CN101474350A discloses a kind of extracting method of total saponin in asparagus, and this method uses alcohol aqueous solvent system
Directly handled after system extraction with macroporous absorbent resin, in the saponin extract of gained, total saponin content is relatively low.
Based on above-mentioned deficiency, a kind of technique is simple, nutritional ingredient retains complete, energy nourishing generate fluid, suitable for cancer patient
The asparagus tablet of auxiliary treatment and preparation method thereof be to be badly in need of in industry.
The content of the invention
In view of above-mentioned analysis, the invention provides a kind of technique is simple, nutritional ingredient retains complete, nourishing generate fluid, it is applicable
The mouth parched and tongue scorched after the auxiliary treatment of cancer and Radiotherapy chemotherapy, poor appetite, general malaise patient's aloe tablet.
A kind of asparagus tablet, is made up of the raw material of following weight：
14000 ~ 16000 parts of fresh asparagus, 100 ~ 140 parts of starch, 70 ~ 90 parts of lactose, 75 ~ 110 parts of microcrystalline cellulose, low substitution hydroxyl
5 ~ 20 parts of propyl cellulose, 10 ~ 30 parts of dextrin, 0.5 ~ 0.7 part of magnesium stearate.
Further, the asparagus tablet is made up of the raw material of following weight：
15000 parts of fresh asparagus, 120 parts of starch, 80 parts of lactose, 92.5 parts of microcrystalline cellulose, low-substituted hydroxypropyl cellulose 12.5
Part, 20 parts of dextrin, 0.6 part of magnesium stearate.
A kind of asparagus tablet and preparation method thereof, is comprised the following steps that：
（1）Feedstock treating：Take new fresh asparagus and cleaned, drained with flowing clear water, cut off, cut into slices；
（2）Vacuum refrigeration：Asparagus after section is placed in vacuum extractor, vacuumizes 2min, is sprayed using liquid nitrogen, is protected
- 20 DEG C of asparagus central temperature is held, and is transferred in -30 DEG C of jelly storehouse and stores for future use；
（3）Ultramicro grinding：Asparagus after freezing is inserted in mechanical micronizer and crushed, obtains 600 mesh above Ultramicro-powder a,
Ultramicro-powder a is obtained into Ultramicro-powder b more than 1000 mesh by air-flow crushing again；
（4）Ultrasound-enhanced extraction：The ethanol solution that Ultramicro-powder b is added to 60% ~ 80% carries out concentration extraction, ethanol solution and asparagus
The liquid-solid ratio of wall cell disruption powder is 5:1~10:1,400 ~ 600w of power, flow back 3 times, each 2h, merge phegma, obtain phegma with
Residue, phegma is concentrated under reduced pressure to obtain concentrate a, reclaims ethanol, asparagus saponin(e is included in concentrate a；
（5）Extraction：Concentrate a is added into the saturation n-butanol aqueous solution that volume ratio is 10 times to extract 3-5 times, combining extraction liquid,
It is concentrated under reduced pressure, dries, obtain coarse powder, reclaims n-butanol；
（6）Elution：Coarse powder is dissolved in the distilled water that mass ratio is 5 times, it is 6 ~ 8 that ratio of height to diameter is added after dissolving:1 macroporous absorption
In resin, the sample of 2 ~ 3 times of column volumes of loading, first with the deionized water of 6 ~ 10 times of column volumes with 0.5 ~ 1 times of cylinder per hour
Long-pending flow velocity elutes and collects water elution b, and the ethanol solution for being then 30% ~ 50% with the content of 4 ~ 5 times of cylinders is with per hour
The flow velocity of 0.5 ~ 1 times of column volume elutes and collects eluent c, merges eluent, and is concentrated under reduced pressure, and reclaims ethanol, is condensed into leaching
Cream, total saponin content are 96.2% ~ 97.1%；
（7）Mixing granulation：Asparagus medicinal extract, starch, lactose, microcrystalline cellulose, low substituted hydroxy-propyl fiber are taken by weight ratio
Element, dextrin are well mixed, and are added the ethanol of raw material total amount 18%, granulation, are dried, whole grain；
（8）Tabletting：Take above-mentioned particle to add the magnesium stearate of parts by weight, be well mixed, tabletting, produce a kind of asparagus tablet.
Further, step（2）The vacuum refrigeration vacuum 86.13kPa.
Further, step（6）The vacuum 0.07MPa that is concentrated under reduced pressure, speed of agitator 60r/min.
Further, step（7）The concentration of alcohol is 55%.
Present invention also offers a kind of purposes of asparagus tablet in the medicine of auxiliary for treating cancer.
The beneficial effects of the present invention are：
（1）Being handled using vacuum refrigeration, the fibrous crystal degree that can be allowed in plant cell declines, and the degree of polymerization improves, released part lignin,
It is fiber fines by raw material tear, while farthest remains the activity of saponin(e and other nutriments in asparagus, improves
The fermented ingredient and utilizing status of asparagus.
（2）Eluted twice using macroporous absorbent resin, effectively increase the purity of asparagus saponin(e, reachable 96.2% ~
97.1%, the saponin(e recoverable through n-butanol after purification is not only sharp without being decolourized in macroreticular resin using ether
In the production of chemical industry, while save production cost.
（3）Using Ultramicro-powder made from two-stage ultramicro grinding, the dissolving of Germinatus Phragmitis extract can be improved and absorbed, finally
Substantially increase the utilization rate of extract.
（4）Using frozen drying method, material recovery rate and the active ingredient rate of transform are improved, so as to improve centre
The quality of product and finished product.
（5）By being refined to bulk drug, invalid components and impurity are removed, on the premise of drug effect is ensured, reduces clothes
Dosage, be advantageous to the preparation of formulation and the application of medicine, improve the modernization level of Chinese medicine.
（6）Experiment shows that the active site that the present invention extracts has obvious anti-tumor function, and because asparagus inherently may be used
It is edible, so it has the characteristics that nontoxic, safe, it is new effective antitumour can be obtained using this active site as active component
Medicine and/or anti-tumor health care product, there is the characteristics of efficient, nontoxic and raw material is cheap and easy to get.
Obviously, according to the above of the present invention, according to the ordinary technical knowledge and customary means of this area, do not departing from
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
Brief description of the drawings
Fig. 1 is asparagus tablet producing technology flow chart.
Embodiment
Embodiment 1
A kind of asparagus tablet（Preparation technology flow is as shown in Figure 1）
（1）Feedstock treating：The new fresh asparagus of 15000kg are taken to clean, drain, cut off, cut into slices to flow clear water；
（2）Vacuum refrigeration：Asparagus after section is placed in vacuum extractor, vacuumizes 2min, is sprayed using liquid nitrogen, is protected
- 20 DEG C of asparagus central temperature is held, and is transferred in -30 DEG C of jelly storehouse and stores for future use, vacuum refrigeration vacuum 86.13kPa；
（3）Ultramicro grinding：Asparagus after freezing is inserted in mechanical micronizer and crushed, obtains 600 mesh above Ultramicro-powder a,
Ultramicro-powder a is obtained into Ultramicro-powder b more than 1000 mesh by air-flow crushing again；
（4）Ultrasound-enhanced extraction：The ethanol solution that Ultramicro-powder b is added to 60% ~ 80% carries out concentration extraction, ethanol solution and asparagus
The liquid-solid ratio of wall cell disruption powder is 5:1~10:1,400 ~ 600w of power, flow back 3 times, each 2h, merge phegma, obtain phegma with
Residue, phegma is concentrated under reduced pressure to obtain concentrate a, reclaims ethanol, asparagus saponin(e is included in concentrate a；
（5）Extraction：Concentrate a is added into the saturation n-butanol aqueous solution that volume ratio is 10 times to extract 3-5 times, combining extraction liquid,
It is concentrated under reduced pressure, dries, obtain coarse powder, reclaims n-butanol；
（6）Elution：Coarse powder is dissolved in the distilled water that mass ratio is 5 times, it is 6 ~ 8 that ratio of height to diameter is added after dissolving:1 macroporous absorption
In resin, the sample of 2 ~ 3 times of column volumes of loading, first with the deionized water of 6 ~ 10 times of column volumes with 0.5 ~ 1 times of cylinder per hour
Long-pending flow velocity elutes and collects water elution b, and the ethanol solution for being then 30% ~ 50% with the content of 4 ~ 5 times of cylinders is with per hour
The flow velocity of 0.5 ~ 1 times of column volume elutes and collects eluent c, merges eluent, and is concentrated under reduced pressure, and reclaims ethanol, is condensed into leaching
Cream, total saponin content are 96.2% ~ 97.1%, the vacuum that is concentrated under reduced pressure 0.07MPa, speed of agitator 60r/min；
（7）Mixing granulation：Take asparagus medicinal extract 702kg, starch 120kg, lactose 80kg, microcrystalline cellulose 92.5kg, low substitution hydroxyl
Propyl cellulose 12.5kg, dextrin 20kg, it is well mixed, adds raw material total amount 18%, the ethanol that concentration is 55%, granulation, do
Dry, whole grain；
（8）Tabletting：Take above-mentioned particle to add magnesium stearate 0.6kg, be well mixed, tabletting, produce a kind of asparagus tablet.
Embodiment 2
A kind of asparagus tablet
Preparation method is simply made up with embodiment 1 of the raw material of following weight：Fresh asparagus 14000kg, starch 100kg,
Lactose 70kg, microcrystalline cellulose 75kg, low-substituted hydroxypropyl cellulose 5kg, dextrin 10kg, magnesium stearate 0.5kg.14000kg
The Germinatus Phragmitis extract 655.2kg that fresh asparagus are prepared.
Embodiment 3
A kind of asparagus tablet
Preparation method is simply made up with embodiment 1 of the raw material of following weight：Fresh asparagus 16000kg, starch 140kg,
Lactose 90kg, microcrystalline cellulose 110kg, low-substituted hydroxypropyl cellulose 20kg, dextrin 30kg, magnesium stearate 0.7kg.
Test example 1
Technological process of the present invention is：Feedstock treating, vacuum refrigeration, ultramicro grinding, it is ultrasound-enhanced extraction, extraction, elution,
Mixing granulation, tabletting.Wherein vacuum refrigeration, ultramicro grinding, elution are the critical process of the present invention, and we make fresh white asparagus
For raw material, using extract yield, extract saponin content and saponin extraction rate as index, ensureing its in addition to critical process
In the case of his technique identical, different critical processes is evaluated, specifically refers to table 1.
The influence that the various processes of table 1 are extracted to asparagus
。
As shown in Table 1, asparagus saponin(e could only be obtained under vacuum refrigeration, ultramicro grinding, secondary elution collective effect
Content 96.94%, far above conventional freezing, broken wall crushing, single elution preparation technology is used merely, illustrate the work in the present invention
Skill is inseparable, mutually collaboration, is an indispensable integrated artistic, only under inventive formulation and process conditions,
The Germinatus Phragmitis extract of saponin content more than 96% can be obtained.
Test example 2
With reference to following experimental data and record, the effect of present invention, is described further, medicine as described below, is real
Apply the formula in example 1.
This laboratory sample is tablet dose, and content is the particle of brown or brown color, and tool asparagus is specifically fragrant, mildly bitter flavor.
Human body recommended dose is daily 2.7g/60kg, and this experiment sets basic, normal, high three dosage groups, is respectively equivalent to human dose
5 times, 10 times and 30 times, orally give sample 28 days.Test result indicates that：Sample has obvious suppression to mouse S180 solid tumor knurl weights
Effect, and has no significant effect to mouse weight, and can improve mouse macrophage phagocytic percentage and phagocytic index and NK is thin
Cytoactive and have no inhibitory action.
Conclusion：Mouth parched and tongue scorched after auxiliary treatment and Radiotherapy chemotherapy suitable for cancer, poor appetite, general malaise patient.
Function of tumor inhibition determines：
1. the influence of pair transplanted tumor：
1.1 sample treatment
Sample is the tablet of brown content, and the suspension of concentration is for examination needed for water is made into.
1.2 experimental animal
Kunming kind female small white mouse, 20 ~ 22 grams of weight range, is provided by Shanghai Medical Univ's Animal House.
1.3 experiment knurl strains
Sarcoma180 (s180), is provided by Sichuan Tumor Hospiatal.
1.4 dose design
The daily recommended dose of sample people is 2.7g/60kg, low dose group 0.225g/kg, middle dose group 0.45g/kg, high agent
Amount group is 1.35g/kg, and positive controls are 25mg/kg endoxan, and negative control group gives distilled water.
1.5 experimental methods and result
Animal extracts the ascitic type S180 mouse ascites of health, after being counted, used according to viable count continuously to sample after three weeks
Normal saline dilution ascites to cell number is 10/ml, every mouse web portion subcutaneous vaccination 0.2ml.Continue after inoculation to sample, ring
Phosphamide group starts to give sample (1g) one day after in inoculation.After inoculation 10 days, mouse is weighed, cervical dislocation is put to death, and takes subcutaneous tumors
Block is weighed, the results detailed in Table 2.
The tumor suppression of table 2 is tested
Note：The solid tumor knurl weight of middle dose group and high dose group is substantially lighter than negative control group（P ＜ 0.05
）, difference is statistically significant；But the solid tumor knurl weight of low dose group and negative control group then no significant difference（P ＞
0.05）.Low dose group, the mouse weight of middle dose group and high dose group and negative control group no significant difference.
2. the influence of pair immunologic function
2.1 sample treatment
Sample is the tablet of brown content, and the suspension of concentration is for examination needed for water is made into.
2.2 animal origin
Kun Ming mice, provided by Sichuan Tumor Hospiatal.
2.3 dose design
The daily recommended dose of sample people is 2.7g/60kg, low dose group 0.225g/kg, middle dose group 0.45g/kg, high agent
Amount group is 1.35g/kg, and control group gives distilled water.
2.4 experimental methods and result
2.4.1 Turnover of Mouse Peritoneal Macrophages phagocytosis chicken red blood cell experiment
After animal continuously gives sample four weeks, the intraperitoneal injection 20g chicken erythrocyte suspension 1ml per mouse, it is spaced 30 minutes, at cervical dislocation
Extremely, it is fixed on mouse plate, cuts off abdominal skin, injecting normal saline 2ml rotates mouse plate 1 minute, suctions out abdominal cavity washing lotion 1ml, point
Drip and incubate 30 minutes on 2 slides, 37 DEG C of incubators are wet, rinsed, dried with physiological saline, fixed with 1: 1 acetone methanol solution,
4%Giemsa ~ phosphate buffer is dyed 3 minutes, then is dried with distilled water rinsing, with oil mirror microscopy, calculate phagocytic percentage and
Phagocytic index, the results detailed in Table 3.
The Macrophage inflammatory protein-1α of table 3
。
Note：Give sample 28 days, four groups of animal phagocytic rates and phagocytic index have raised, but middle dose group and high dose
Group compares control group, and its elevated phagocytic rate and phagocytic index difference are more notable（P ＜ 0.05）, between low dose group and control group
Then no significant difference.
2.4.2NK cytoactive detection
After animal continuously gives sample four weeks：Cervical dislocation is put to death, and takes spleen, splenocyte suspension is made, and 24hYAC ~ 1 is thin after taking passage
Born of the same parents add 3H ~ TdR 10u Ci/1 × 106/ml, and 37 DEG C are cultivated 2 hours, are shaken 1 time within every 30 minutes, are washed 3 times, matched somebody with somebody with nutrient solution
The target cell of 1 × 105/ml YAC ~ 1 is made and adds 96 well culture plates, 100ul is added per hole, test hole adds 100ul1 × 107/ml
Mouse boosting cell suspension, blank control wells add 100ul nutrient solutions, and maximum release aperture adds 100ul2.5%TritonX ~ 100,
Each sample sets 3 multiple holes, is collected cell in 49 type glass fiber filter papers with bull cell harvestor after 37 DEG C of culture 4h,
60 DEG C dry after immerse scintillation solution stay overnight, with liquid glimmer instrument measure CPM, the results detailed in Table 4.
The NK cytoactive detections of table 4
。
Note：Give sample 28 days, four groups of animal NK cytoactives have raised, but low dose group, middle dose group, high agent
Amount group compares the NK cytoactives of control group, and difference has statistical significance（P ＜ 0.05）.
In summary, oral asparagus tablet is used for the body weight for having the mouse of solid tumor and had no significant effect, but solid tumor knurl
Weight but significantly mitigates, and the phagocytosis ratio and phagocytosis index of macrophage is also significantly raised, and the NK cytoactives after medication are also obviously improved,
The growth of tumour can effectively be suppressed by illustrating asparagus tablet, while can also improve immunologic function.
Claims (7)
1. a kind of asparagus tablet, it is characterised in that the asparagus tablet is made up of the raw material of following weight：
14000 ~ 16000 parts of fresh asparagus, 100 ~ 140 parts of starch, 70 ~ 90 parts of lactose, 75 ~ 110 parts of microcrystalline cellulose, low substitution hydroxyl
5 ~ 20 parts of propyl cellulose, 10 ~ 30 parts of dextrin, 0.5 ~ 0.7 part of magnesium stearate.
2. asparagus tablet according to claim 1, it is characterised in that the asparagus tablet by following weight raw material
It is made：
15000 parts of fresh asparagus, 120 parts of starch, 80 parts of lactose, 92.5 parts of microcrystalline cellulose, low-substituted hydroxypropyl cellulose 12.5
Part, 20 parts of dextrin, 0.6 part of magnesium stearate.
3. a kind of preparation method of asparagus tablet according to claim 1 or 2, it is characterised in that this method includes following
Step：
（1）Feedstock treating：Take new fresh asparagus and cleaned, drained with flowing clear water, cut off, cut into slices；
（2）Vacuum refrigeration：Asparagus after section is placed in vacuum extractor, vacuumizes 2min, is sprayed using liquid nitrogen, is protected
- 20 DEG C of asparagus central temperature is held, and is transferred in -30 DEG C of jelly storehouse and stores for future use；
（3）Ultramicro grinding：Asparagus after freezing is inserted in mechanical micronizer and crushed, obtains 600 mesh above Ultramicro-powder a,
Ultramicro-powder a is obtained into Ultramicro-powder b more than 1000 mesh by air-flow crushing again；
（4）Ultrasound-enhanced extraction：The ethanol solution that Ultramicro-powder b is added to 60% ~ 80% carries out concentration extraction, ethanol solution and asparagus
The liquid-solid ratio of wall cell disruption powder is 5:1~10:1,400 ~ 600w of power, flow back 3 times, each 2h, merge phegma, obtain phegma with
Residue, phegma is concentrated under reduced pressure to obtain concentrate a, reclaims ethanol, asparagus saponin(e is included in concentrate a；
（5）Extraction：Concentrate a is added into the saturation n-butanol aqueous solution that volume ratio is 10 times to extract 3-5 times, combining extraction liquid,
It is concentrated under reduced pressure, dries, obtain coarse powder, reclaims n-butanol；
（6）Elution：Coarse powder is dissolved in the distilled water that mass ratio is 5 times, it is 6 ~ 8 that ratio of height to diameter is added after dissolving:1 macroporous absorption
In resin, the sample of 2 ~ 3 times of column volumes of loading, first with the deionized water of 6 ~ 10 times of column volumes with 0.5 ~ 1 times of cylinder per hour
Long-pending flow velocity elutes and collects water elution b, and the ethanol solution for being then 30% ~ 50% with the content of 4 ~ 5 times of cylinders is with per hour
The flow velocity of 0.5 ~ 1 times of column volume elutes and collects eluent c, merges eluent, and is concentrated under reduced pressure, and reclaims ethanol, is condensed into leaching
Cream, total saponin content are 96.2% ~ 97.1%；
（7）Mixing granulation：Asparagus medicinal extract, starch, lactose, microcrystalline cellulose, low substituted hydroxy-propyl fiber are taken by weight ratio
Element, dextrin are well mixed, and are added the ethanol of raw material total amount 18%, granulation, are dried, whole grain；
（8）Tabletting：Take above-mentioned particle to add the magnesium stearate of parts by weight, be well mixed, tabletting, produce a kind of asparagus tablet.
4. the preparation method of asparagus tablet according to claim 3, it is characterised in that step（2）The vacuum refrigeration is true
Reciprocal of duty cycle 86.13kPa.
5. the preparation method of asparagus tablet according to claim 3, it is characterised in that step（6）It is described to be concentrated under reduced pressure very
Reciprocal of duty cycle 0.07MPa, speed of agitator 60r/min.
6. the preparation method of asparagus tablet according to claim 3, it is characterised in that step（7）The concentration of alcohol is
55%。
7. purposes of the asparagus tablet according to claim 1-6 any one in the medicine of auxiliary for treating cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710763490.4A CN107375757A (en) | 2017-08-30 | 2017-08-30 | A kind of asparagus tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710763490.4A CN107375757A (en) | 2017-08-30 | 2017-08-30 | A kind of asparagus tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107375757A true CN107375757A (en) | 2017-11-24 |
Family
ID=60348215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710763490.4A Pending CN107375757A (en) | 2017-08-30 | 2017-08-30 | A kind of asparagus tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107375757A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6194660A (en) * | 1984-10-15 | 1986-05-13 | 松下電工株式会社 | Deodorant |
| CN1840067A (en) * | 2006-01-17 | 2006-10-04 | 山东轻工业学院 | Chewing tablet of asparagus and preparation process thereof |
| CN101559157A (en) * | 2009-05-18 | 2009-10-21 | 华东师范大学 | Method for fractional extraction of asparagus saponin and asparagus amylose using asparagus slag |
| CN101791371A (en) * | 2009-12-22 | 2010-08-04 | 沈阳亿灵医药科技有限公司 | Method for preparing saponin by extracting asparagus officinalis L |
| CN102258193A (en) * | 2011-07-19 | 2011-11-30 | 江西省农业科学院 | Production method of asparagus chewable tablets |
-
2017
- 2017-08-30 CN CN201710763490.4A patent/CN107375757A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6194660A (en) * | 1984-10-15 | 1986-05-13 | 松下電工株式会社 | Deodorant |
| CN1840067A (en) * | 2006-01-17 | 2006-10-04 | 山东轻工业学院 | Chewing tablet of asparagus and preparation process thereof |
| CN101559157A (en) * | 2009-05-18 | 2009-10-21 | 华东师范大学 | Method for fractional extraction of asparagus saponin and asparagus amylose using asparagus slag |
| CN101791371A (en) * | 2009-12-22 | 2010-08-04 | 沈阳亿灵医药科技有限公司 | Method for preparing saponin by extracting asparagus officinalis L |
| CN102258193A (en) * | 2011-07-19 | 2011-11-30 | 江西省农业科学院 | Production method of asparagus chewable tablets |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102417544B (en) | Ziyang selenium-rich green tea selenium-containing polysaccharide, and preparation method and application thereof | |
| CN102988827A (en) | Dendrobium officinale granula | |
| CN102988828A (en) | Preparation method of dendrobium officinale granula | |
| CN106108031A (en) | Garlic skin dietary fiber and high temperature steaming thereof and enzymolysis modified technology of preparing and application | |
| CN104013636B (en) | Watt careless Pentacyclic triterpene saponins compounds anti-tumor drug purposes | |
| CN108186803A (en) | The preparation process of compound oral liquid for tonifying blood containing red skin of peanut | |
| CN101664180A (en) | Health-care nutritional complexing agent with effect of and preparation method thereof | |
| CN103734696B (en) | A kind of soft capsule and preparation method thereof improving immunity, protection internal organs | |
| CN106619782A (en) | Herba rhodiolae extract and healthy product containing herba rhodiolae extract | |
| CN106983786B (en) | A kind of Chinese medicine composition for preventing and/or treating hyperlipemia and preparation method thereof | |
| WO2020000828A1 (en) | Gracilaria lemaneiformis polysaccharide having significant hypolipidemic activity and preparation method therefor and use thereof | |
| CN107375757A (en) | A kind of asparagus tablet and preparation method thereof | |
| CN101804083B (en) | Application of pollen pini and extract thereof in treating inflammatory bowel disease and method for preparing extract | |
| CN104771595B (en) | A kind of Chinese medicine composition of strengthen immunity and preparation method thereof | |
| CN104189038B (en) | Chinese medicine preparation for nursing one's health female pathology health and immunologic function | |
| CN103784492B (en) | Common pratia herb extract and its application with antitumor action | |
| CN107412607A (en) | A kind of asparagus capsule and preparation method thereof | |
| CN106511409A (en) | Compound papaya seed alcohol extract and application thereof in boosting immunity | |
| CN102526145A (en) | Acanthopanax senticosus leaf extract capable of protecting liver from alcoholic injury | |
| CN112076292A (en) | Powder with functions of enhancing immunity and regulating kidney yin deficiency and preparation method thereof | |
| CN111150811A (en) | Formula of blood sugar reducing powder | |
| CN106038869B (en) | A kind of compound guava preparation and preparation method thereof | |
| CN104840747B (en) | Chinese medicine composition with antithyroid cancer activity and its preparation method and application | |
| CN110403967A (en) | A kind of increase ginsenoside Rg3、Rh2The processing of Panax ginseng method of content and obtained processed ginseng and application | |
| CN108743840A (en) | A kind of Chinese medicine composition and preparation method thereof with auxiliary lipid-lowering function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171124 |